Isis Pharmaceuticals (ISIS +0.1%) plans to start Phase II trials of its STAT3RX treatment in...

|By:, SA News Editor

Isis Pharmaceuticals (ISIS +0.1%) plans to start Phase II trials of its STAT3RX treatment in patients with advanced cancer after "impressive" preliminary data in a Phase I study. The early results suggest that the "drug can produce responses in patients with advanced cancer who have failed to respond to other therapies," says David Hong of the University of Texas. (PR)